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Abstract: Ziel: Das Ziel dieser Studie war die Optimierung der Photodynamischen Therapie (PDT) mit-
tels eines neuen liposomalen Photosensibilisators (Fospeg). Damit wird eine Verringerung systemischer
Reaktionen angestrebt. Material und Methoden: Zur Untersuchung der pharmakokinetischen Eigen-
schaften von Fospeg haben wir Gewebe- und Plasmaparameter bei Katzenpatienten mit spontanen Plat-
tenepithelkarzinomen bestimmt. Messungen der in vivo-Fluoreszenzintensität von Tumor und Haut wur-
den mittels eines Spektrophotometers nach intravenöser Injektion von m-THPC (Foscan® oder Fospeg)
bei 10 Katzen ermittelt. Zu verschiedenen Zeitpunkten nach Gabe des Photosensitibilisators wurden Blut-
proben mittels HPLC (High performance liquid chromatography) analysiert. Ergebnisse: Keine der mit
Fospeg behandelten Katzen zeigte Nebenwirkungen während oder nach Verabreichung des Medikaments.
Fluoreszenzintensitäten, Bioverfügbarkeit sowie der Fluoreszenzquotient (Tumorfluoreszenz geteilt durch
Hautfluoreszenz) im Tumor waren 2- bis 4-mal höher mit Fospeg verglichen mit Foscan®. Die Fospeg-
Konzentration im Tumor stieg konstant an bis 4 Stunden nach der Injektion ein Maximum erreicht wurde.
Konzentration und Bioverfügbarkeit im Plasma waren bei Fospeg ungefähr 3-mal höher als bei Foscan®.
Die Halbwertszeit der Verteilung war kürzer mit Fospeg. Dadurch trat eine maximale Akkumulation im
Tumor 5.5-mal früher auf. Maximale Akkumulation im Tumor sowie maximale Fluoreszenzquotienten
traten bei Fospeg gleichzeitig auf, was eine maximale Selektivität bedeutet. In beiden Gruppen sprachen
alle Katzen auf die Therapie an. Schlussfolgerung: Fospeg wurde von allen Katzen gut vertragen und
scheint Foscan® bezüglich der pharmakokinetischen Eigenschaften überlegen zu sein. Purpose: The aim
of the present study was to optimize and simplify photodynamic therapy (PDT) using a new liposomal
formulation (Fospeg) of the photosensitizer m- THPC (meta(tetrahydroxyphenyl)chlorin), and to reduce
systemic reactions to the photosensitizer. Experimental Design: To examine the pharmacokinetics of
Fospeg, we determined tissue and plasma parameters in feline patients with spontaneous squamous cell
carcinoma. In vivo fluorescence intensity measurements of tumor and skin were performed with a fiber
spectrophotometer after intravenous injection of m-THPC (either Foscan® or Fospeg) in 10 cats. Blood
samples, drawn at several time points after photosensitizer administration, were analyzed by HPLC (High
performance liquid chromatography). Results: None of the Fospeg treated cats showed side effects during
or after drug injection. Fluorescence intensities, fluorescence ratios (tumor fluorescence divided by skin
fluorescence) and bioavailability in the tumor were 2 to 4 times higher with Fospeg compared to Foscan®.
Fospeg concentration in the tumor increased constantly to reach a maximum at 4 hours after injection.
Plasma concentration and plasma bioavailability were about 3 times higher with Fospeg compared to
Foscan® measured at the time points of highest plasma concentration. The distribution half-life was
shorter with Fospeg, resulting in maximal tumor accumulation up to 5.5 times earlier. Maximal tumor
accumulation and maximal fluorescence ratio with Fospeg occurred at the same time point, indicating
maximal selectivity. In both groups all cats responded to therapy. Conclusions: Fospeg was well tol-
erated by all cats and appears to have superior pharmacokinetic properties compared to Foscan®. The
efficacy of the drug warrants further study.
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ABSTRACT 
 
Purpose: The aim of the present study was to optimize and simplify photodynamic therapy 
(PDT) using a new liposomal formulation (Fospeg) of the photosensitizer m-THPC 
(meta(tetrahydroxyphenyl)chlorin), and to reduce systemic reactions to the photosensitizer.  
Experimental Design: To examine the pharmacokinetics of Fospeg, we determined tissue and 
plasma parameters in feline patients with spontaneous squamous cell carcinoma. In vivo 
fluorescence intensity measurements of tumor and skin were performed with a fiber 
spectrophotometer after intravenous injection of m-THPC (either Foscan® or Fospeg) in 10 cats. 
Blood samples, drawn at several time points after photosensitizer administration, were analyzed 
by HPLC (High performance liquid chromatography).  
Results: None of the Fospeg treated cats showed side effects during or after drug injection. 
Fluorescence intensities, fluorescence ratios (tumor fluorescence divided by skin fluorescence) 
and bioavailability in the tumor were 2 to 4 times higher with Fospeg compared to Foscan®. 
Fospeg concentration in the tumor increased constantly to reach a maximum at 4 hours after 
injection. Plasma concentration and plasma bioavailability were about 3 times higher with 
Fospeg compared to Foscan® measured at the time points of highest plasma concentration. The 
distribution half-life was shorter with Fospeg, resulting in maximal tumor accumulation up to 
5.5 times earlier. Maximal tumor accumulation and maximal fluorescence ratio with Fospeg 
occurred at the same time point, indicating maximal selectivity. In both groups all cats 
responded to therapy.  
Conclusions: Fospeg was well tolerated by all cats and appears to have superior 
pharmacokinetic properties compared to Foscan®. The efficacy of the drug warrants further 
study.
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INTRODUCTION 
The first reports on photodynamic therapy (PDT) date back to the beginning of the last century, 
when researchers observed that a combination of light with hematoporphyrin induces cell death 
(1). In 1995 the U.S. Federal Food and Drug Administration (FDA) approved PDT as a novel 
form of therapy against cancer and since then, PDT has been used more frequently.  
PDT includes two components combined to induce cellular and tissue effects in an oxygen 
dependent manner. The first is a “light-sensitive” substance called the photosensitizer. The 
second is light of a specific wavelength (laser light) to maximally activate the tumor-localized 
photosensitizer. Upon activation, a photosensitizer undergoes type I (electron or hydrogen 
transfer) or type II (local generation of cytotoxic singlet oxygen) photochemical reactions. 
Tumor destruction associated with PDT involves three principal mechanisms (2): 1) Direct 
tumor cell kill (3), 2) destruction of tumor-associated vasculature (4-6) and 3) activation of an 
immune response against tumor cells (7, 8). A short drug-light interval allows the 
photosensitizer to accumulate predominantly in the vascular compartment. PDT-mediated 
vascular effects range from transient vascular spasm, vascular stasis and thrombus formation up 
to total permanent vessel occlusion and can include enhanced vascular leakiness (5). A longer 
drug-light interval results in maximal concentration of the photosensitizer in the tumor causing 
direct tumor cell destruction. This was shown recently for the second generation photosensitizer 
Foscan® (meta(tetrahydroxyphenyl)chlorin; m-THPC) and indicates that the in vivo effects 
occur via an indirect vascular as well as a more direct effect at different drug-light intervals (9, 
10).  
In order to optimize PDT, liposomes are presently being tested as carrier and delivery systems 
with the aim of improving the tumoritropic behavior of photosensitizers.  
The present study was thus designed to optimize PDT in cat patients with spontaneous 
cutaneous squamous cell carcinomas using a new, liposomal formulation of m-THPC, called 
Fospeg. Pet animals with spontaneously developing cancer provide an excellent opportunity to 
study many aspects of cancer from etiology to treatment. Squamous cell carcinomas are 
common neoplasms in cats. Similar to human cutaneous squamous cell carcinoma, there is an 
etiologic correlation between development of the neoplasm and exposure to ultraviolet light 
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(12). Several studies have shown the efficacy of PDT in the treatment of feline squamous cell 
carcinoma (13-16).  
The aim of the present study was to investigate the accumulation of Fospeg in tumor and skin in 
situ with a spectrophotometer and to define the plasma pharmacokinetics in cats. We 
hypothesized, that with Fospeg, a higher tumor to skin ratio and an earlier m-THPC 
concentration peak in plasma and neoplastic tissue could be achieved.  
 
PATIENTS, MATERIALS AND METHODS 
Animal Patients 
Ten pet cats with histologically confirmed cutaneous squamous cell carcinoma were included in 
the study. Tumors were clinically staged using a modification of the World Health Organization 
(WHO) system (15) and included thoracic radiographs, blood analysis (hematology and organ 
parameters), regional lymph node aspiration and urinalysis. 
All animal treatments were conducted according to the approval issued by the official veterinary 
authorities of the Canton of Zurich. All animal owners signed a written informed consent. 
 
Photosensitizers 
The original lipophilic formulation of m-THPC (Foscan®, 1.5 mg/ml, 3 ml vials) and the new 
liposomal formulation of m-THPC (Fospeg, 1.5 mg/ml, 3 ml vials) were used, kindly provided 
by Biolitec AG, Jena, Germany. m-THPC is practically insoluble in all aqueous media. The 
single component is of > 99% purity with its fluorescence emission peak in the red at 652 nm. 
The molecular weight of m-THPC is 680.24 Daltons.  
Fospeg basically comprises DPPC (dipalmitoylphosphatidyl choline), DPPG 
(dipalmitoylphosphatidyl glycerol) and pegylated DSPE (pegylated distearoylphosphatidyl 
ethanolamine) as liposome forming compounds. The physical stability of the liposomal 
formulation was assessed by monitoring the particle size distribution using photon correlation 
spectroscopy. The mean particle size was approximately 140 nm. The degree of pegylation was 
2.5-5%, and the degree of m-THPC was 10%. The drug is associated with the lipid membrane of 
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the unilamellar liposomes. The liposomal m-THPC formulation can be diluted with aqueous 
media or biological fluids without precipitation. 
 
Drug application 
All animals received 0.15 mg m-THPC/kg body weight out of the same production lot of either 
Foscan® or Fospeg. The drug was continuously injected into a cephalic or femoral vein over 10 
minutes. Cats that were given Foscan® were premedicated with Clemastin (Tavegyl®, Novartis 
Consumer Health Schweiz AG Bern; 0.05 mg/kg), a H1-receptor antihistamine. Cats receiving 
Fospeg were not premedicated, in order to observe systemic reactions if any.  
For all measurements, the time t = 0 corresponded to the end of the injection.  
 
Spectrophotometric fluorescence measurements 
In vivo fluorescence measurements were performed non-invasively a) in normal skin 
(unpigmented) and b) in the tumor every hour for the first 10 h and then 16, 24, 36 (Foscan® 
group only), 48 and 72 h after drug injection. A fiber spectrometer (optical biopsy system, OBS, 
kindly provided by Dr. Martin O’Dwyer, University of Glasgow, UK and Biolitec, Jena, 
Germany) was used. This instrument is composed of a 405 nm laser diode excitation source, an 
optical fiber, and a spectrometer. Emission from the tissue was collected and after suitable 
filtering, the spectra from 450 to 700 nm were displayed (integration time 500 ms). Intensity 
values at 652 nm were recorded. Photobleaching at the surface was not relevant due to short 
acquisition times and a low power at the end of the fiber (30 µW). The tip of the fiber was held 
perpendicular to the surface of the tissue exerting constant pressure to assure contact. At each 
location 3 individual measurements were obtained and the mean value was determined. The 
spectrophotometer was calibrated at zero (dark current) prior to each measurement. 
 
Photosensitizer concentration in plasma/urine 
To determine the plasma concentration of m-THPC, blood samples were obtained 1, 3, 6, 8, 16, 
24, 48 and 72 hours after application of the photosensitizer.  
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The 1 - 1.5 ml blood samples were collected in sterile CTAD tubes (Becton Dickinson AG, CH-
4002 Basel, Switzerland). The tubes were immediately centrifuged for 30 min at 2’500 g and 
4°C. The plasma supernatant was stored at –80°C. The plasma m-THPC concentration was 
measured by HPLC (Biolitec AG, Jena, Germany). A weighted sample of 20 mg was blended 
with 1.5 ml of DMSO/methanol (5:3, v/v) and agitated for 12 hours at 60°C. Afterwards, the 
samples were centrifuged for 5 min at 13’000 g and 1 ml of the clear supernatant was removed 
for HPLC analysis (Gold System Module 168, Beckman + Fluorescence detector RF-10A XL, 
Shimadzu, Column: "LiChroCART 250-4" with Purospher STAR RP-18 end capped; 5 µm; 
(Merck), Guard column: "LiChroCART 4-4" with Purospher STAR RP-18e; 5 µm (Merck), 
Temperature: 30 °C, Mobile phase: acetonitrile: H2O + 0.1 % trifluoroacetic acid = 57.5% (v/v) 
: 42.5% (v/v), Flow rate: 1 ml/min.). The fluorescence wavelength was set at 410 nm for 
excitation and 653 nm for emission. The plasma m-THPC concentration was calculated from a 
calibration curve constructed by plotting the peak height values of m-THPC standard solutions 
versus their concentrations. 
Urine samples were taken at different time points after injection and analyzed by HPLC for 
potential m-THPC content. 
 
Treatment 
PDT of the spontaneous cutaneous carcinomas in client owned cats was performed under 
anesthesia 48 h after Foscan® injection and 16 h after Fospeg injection. The interval of 48 h for 
Foscan® was based on previous experience in cats (13). For Fospeg, the shorter interval of 16 h 
was based on results from laboratory mice, that indicated a more rapid metabolism for the 
liposomal formulation (Dr. Susanna Gräfe, Biolitec, unpublished data). 
A 652 nm diode laser (Applied Optronics Corp., South Plainfield, NJ) was used as light source. 
The light was delivered using a quartz optical fiber with a micro lens at the tip (Medlight SA, 
Ecublens, Switzerland). Non-contact surface illumination of the entire tumor area plus a security 
margin of 5 mm was implemented. The power at the end of the fiber was measured by a 
calibrated power meter at 652 nm and the laser was adjusted to obtain a 0.05 W/cm2 non-
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thermal power density on the irradiated surfaces. A dose of 10 J/cm2 was delivered and the 
treatment time (200 sec) was controlled with the laser`s built in countdown timer. 
Anesthesia was induced by intravenous application of Buprenorphin (Temgesic®, ESSEX 
Chemie AG, 6005 Luzern, Switzerland; 10µg/kg), Midazolam (Dormicum®, Roche Pharma AG, 
Reinach, Switzerland; 0.2 mg/kg iv) and Propofol (Propofol®, Fresenius Kabi AG, Stans, 
Switzerland). Propofol was given until tracheal intubation was possible. Anesthesia was 
maintained with Isofluran (Forene®, Abbott AG, Baar, Switzerland; 1-3% in oxygen). 
Hemoglobin oxygen saturation and heart rate were monitored continuously throughout 
anesthesia with a pulse oxymeter, and values were recorded before and during illumination. 
Ringer’s lactate solution was administered intravenously at 4 ml kg-1 h-1. 
Post-treatment the cats received Buprenorphin (10 µg/kg) every 8 h for 48 hours. The following 
3 weeks they received Piroxicam (Pirocam®, Spirig Pharma AG, 4622 Egerkingen, Switzerland; 
0.3 mg/cat) once a day as pain medication. If necessary, amoxicillin and clavulanic acid 
(Synulox®, Pfitzer AG, 8048 Zürich, Switzerland; 12.5 mg/kg twice a day) was given.  
 
Toxicity 
Acute toxicity was assessed during and after photosensitizer administration. Blood and urine 
samples were taken 72 h after injection of the photosensitizer to rule out an effect of the drug on 
organ parameters. Tissue reactions were assessed during, 1 hour and 4 days after light treatment. 
Toxicity was scored according to CTCAE v3.0 (Common Terminology Criteria for Adverse 
Events). 
 
Statistical analysis 
Pharmacokinetic values were obtained by using Pharmacokinetic (PK) Functions for Microsoft 
Excel. Description of data is given by mean and median (± standard deviation; SD). Stat View 
5.0.1 software was used for statistical analysis. Data were investigated graphically by box plots. 
In order to investigate differences between both drugs with respect to tissue fluorescence and 
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plasma parameters, the Mann-Whitney-U-test was applied. P values < 0.05 were considered 
significant. 
 
 
RESULTS 
Animal patients 
All patients included in the study were European short hair cats. Four of the patients were 
female spayed, 6 were male neutered. There was no statistically significant difference 
concerning gender, age or weight between the two groups. All tumors (n=10) were classified as 
squamous cell carcinoma by histopathological examination. All tumors were located on the 
head with the majority of tumors occurring on the nasal planum (n=6). Most of the treated 
squamous cell carcinomas were low stage tumors (T1a-T2a; n=7). None of the cats had 
evidence of metastatic disease (N0M0). 
 
Spectrophotometric fluorescence measurements  
Patients receiving Foscan® showed mean and median maximal tumor fluorescence intensities of 
160.88 and 154.89 (relative units), respectively. These maxima were seen between 36 and 48 h 
after injection (Table 1). In patients treated with Fospeg, the mean and median maximal m-
THPC fluorescence intensities in the tumor were 275.67 and 279.00 (relative units), 
respectively. In this group, maxima were reached 5 to 10 h after injection (Table 1). The 
fluorescence intensity maxima were not significantly different (P= 0.139), even though a 
distinct difference is obvious (Figure 1). The intensity increased rapidly over the first 4 h to 
reach a maximum and a plateau phase 4 to 6 h after Fospeg injection. The time point of intensity 
maxima differed significantly (P= 0.015) between the two groups. The fluorescence ratio, 
defined as the mean fluorescence intensity of the tumor divided by the mean fluorescence 
intensity of normal skin at a given time point, was calculated for each individual animal. For 
Foscan®, these ratios ranged from 1.79 to 4.81 (mean and median values of 3.02 and 2.45, 
respectively). For Fospeg, the ratios ranged from 3.47 to 18.34 (mean and median value of 
10.75 and 11.98, respectively). The fluorescence ratio was higher for Fospeg compared to 
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Foscan® (Figure 1), although statistical significance was not achieved (P=0.053). Highest ratios 
were reached much later after injection of Foscan® than after injection of Fospeg (Table 1); with 
Fospeg a rapid increase during the first 5 to 10 h could be observed. For Fospeg only, the time 
point of the maximal fluorescence intensities and the time point of the highest tumor to skin 
ratio were identical.  
The mean and median bioavailability in the tumor, calculated for the first 16 h after injection 
(area under the curve; AUC16) was significantly higher for Fospeg than for Foscan® (P=0.030; 
Figure 2). The bioavailability in the skin was similar for both photosensitizers (P=0.305). The 
AUC16-ratio, calculated from the tumor values divided by the skin values, for Foscan® resulted 
in a mean and median of 2.00 and 1.55, whereas the AUC16-ratio for Fospeg showed mean and 
median values of 6.94 and 6.50, respectively (P= 0.053; Table 1).         
 
Photosensitizer concentration in plasma/urine 
In the Foscan® group, mean and median maximal m-THPC levels of 431.38 and 458.81 ng/ml 
plasma were reached during the first 8 h after injection. During this time range, m-THPC levels 
remained constant or increased slightly. Afterwards, the photosensitizer concentration decreased 
to reach a level near baseline 48 h after injection. For Foscan®, the calculated distribution half-
life (hour 0-16) resulted in mean and median values of 46.74 and 44.62 h, respectively. The 
calculated elimination half-life (hour 16-72) showed mean and median values of 20.64 h and 
20.32 h, respectively (Table 2). In the Fospeg group, significantly higher mean and median 
maximal m-THPC levels were found (1317.08 and 1523.30 ng/ml plasma, respectively), 
compared to the Foscan® group (P= 0.017). The highest m-THPC plasma levels were seen at the 
first time point measured, followed by an immediate and rapid disappearance of the 
photosensitizer signal (Figure 3). For Fospeg, the calculated distribution half-life (hour 0-16) 
was significantly shorter (P=0.017), resulting in mean and median values of 9.36 and 7.95 h. 
The calculated elimination half-life (hour 16-72) resulted in mean and median values of 22.90 
and 19.83 h, which was comparable to the values obtained with Foscan® (P= 0.732; Table 2). 
Plasma drug concentrations returned to near baseline 48 h after injection. 
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The mean and median bioavailability, calculated at 16 and at 72 h, was much lower in the 
Foscan® group compared to the Fospeg group (P= 0.053 and P= 0.087, respectively; Table 2).  
m-THPC could not be detected in the urine at any of the time points examined after injection. 
Treatment response 
All 3 cats in the Foscan® group had a complete response to therapy. No tumor recurrence could 
be observed so far. In the Fospeg group 4 cats had a complete, 3 a partial response. Two of 
these three cats had tumor recurrences and no further therapy was done, while 1 cat was 
retreated with PDT and then had a complete response. No tumors have recurred in the cats with 
a complete response. The longest follow up time in both therapy groups, however, is only 380 
days.  
Toxicity 
During or shortly after Foscan® injection, 2 of the 3 cats showed side effects such as tachypnoe, 
salivation and excitation, even though they were premedicated. 
The Fospeg injection was well-tolerated by all cats. None of the Fospeg treated animals showed 
signs of acute toxicity, such as vomiting, diarrhea, salivation, tachypnoe, excitation or death. 
There was no obvious difference in skin reaction between the 2 groups. Only 1 cat in the Fospeg 
group (patient 7), which had extremely high skin fluorescence intensities, developed sunburn-
like reactions on the face about 10 days after injection which healed uneventfully. 
 
DISCUSSION 
PDT has the potential to be a powerful treatment modality for cancer, either applied solitary or 
in combination with chemotherapy (17), surgery (18), radiotherapy  (19) or other strategies, 
such as hyperthermia (20). However, low selectivity, inconveniently long drug-light intervals, 
and prolonged generalized photosensitivity are problems encountered with this therapy 
modality. Modifying the photosensitizing moiety through its physicochemical properties may 
improve PDT.  
In the present study, a new formulation of a commercially available photosensitizer has been 
studied to address the following hypotheses: the liposomal formulation 1) allows a shorter drug-
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light interval, 2) results in a higher tumor to skin ratio and 3) shows an earlier plasma peak, 
compared to the conventional formulation.    
Maximal tumor fluorescence intensities with Fospeg were nearly twice as high compared to 
Foscan®. This is important clinically, as the drug dose needed could probably be lowered. A 
lower drug dose would result in a shorter generalized photosensitivity of the patients. With 
Fospeg, the time of maximal fluorescence intensity in the tumor was shown to be significantly 
earlier than with Foscan® (P= 0.015). These results suggest that the drug-light interval could be 
reduced by a factor of 5.5, representing a second relevant advantage for clinics and fulfilling the 
first hypothesis. For Fospeg, the time point of maximal tumor accumulation was in accordance 
with the time of maximal tumor to skin ratio. For Foscan®, this was not the case in the present 
study. In previously published work using Foscan®, a drug-light interval of 4 to 12 h resulted in 
extensive skin and muscle necrosis (21, 22), indicating a low tumor to normal tissue ratio at this 
early time point. In contrary, no obvious changes in normal tissues were observed at any drug-
light interval when pegylated m-THPC was used (23). Results of our study clearly show much 
higher tumor to skin ratios in spontaneous feline squamous cell carcinoma with the liposomal 
drug. In general, the uptake of pegylated photosensitizers is enhanced due to an increased 
vascular permeability of tumor vessels. In addition, tumor tissue lacks a functional lymphatic 
system, therefore, extravasated macromolecules can not return efficiently to the central 
circulation. By showing a 4 times higher maximal tumor to skin ratio for Fospeg compared to 
Foscan®, we proved our second hypothesis. A mean fluorescence ratio of about 12 indicates a 
distinct selectivity of the new formulation. The lack of statistical significance may be due to the 
fairly small sample size in each group, although a clear trend was seen (P=0.053).  
The results reported here point at differences of 3 to 4 orders of magnitude for Fospeg compared 
to Foscan® in terms of changes in AUC, which means a significantly higher bioavailability for 
the new liposomal m-THPC formulation (P=0.030). This suggests again the possibility to 
decrease the typical administered dosage of m-THPC. Also, the AUC16-ratio for Fospeg is about 
4 times higher than for Foscan®, showing a much higher overall accumulation in the tumor than 
in the skin.  
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For Fospeg, the maximal plasma m-THPC levels were about 3.5 times higher than for Foscan® 
(P= 0.017). With Fospeg, the maximum plasma concentration was attained at the first time point 
measured, while for Foscan® maximum plasma concentrations were seen about 6 h after 
injection. For the lipophilic m-THPC a delayed concentration maximum has been shown in the 
plasma of humans, dogs, cats, rabbits and nude rats (24). Reasons for this phenomenon, such as 
aggregation of hydrophobic substances such as Foscan®, can be substantially decreased by using 
liposomal formulations. Therefore, our third hypothesis of an earlier plasma peak after Fospeg 
injection was confirmed. The mean half-lives calculated for Foscan® as well as the shape of the 
graphs are similar to those of a previous study in cats (25). The shorter distribution half-life of 
Fospeg could be the reason for the earlier maximal photosensitizer accumulation in the tumor.  
We did not see any complication during injection of Fospeg. During and after the injection of 
Foscan®, 2 of 3 cats showed side effects such as tachypnoe, salivation and excitation. 
Premedication was used because in previously treated cats these symptoms were seen at our 
institution. These side effects led to the discontinuation of Foscan® after 3 cats. Cats in the 
Fospeg group were not premedicated because this could have masked even weak side effects. 
The owners were told to keep the cats away from direct sunlight for another 10 days. The one 
cat that developed pronounced skin reactions was, in addition to a very low tumor to skin 
AUC16, housed at high altitude and went outside 1 week after injection.  
   
In this study we examined tumor, skin and plasma drug levels in order to generate an optimized 
and simplified PDT protocol. In a recent report (10) no significant correlation between tumor 
drug level and PDT response, but between plasma drug level and tumor response was found for 
Foscan®-PDT. This suggests that illumination in clinical PDT should be performed at highest 
plasma levels, targeting the vasculature more than the tumor cell directly. In another study, 
Foscan®-PDT had two peaks of activity: an early effect on tumor vasculature synchronous to the 
plasma peak level, followed by a late direct effect at maximum tumor accumulation (9). After 
having determined the tumor and tissue peaks in the feline species, our next step will be to 
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compare the PDT outcome of the cats treated to date with cats treated optimally, i.e. at the time 
of highest Fospeg tumor accumulation versus cats treated at the time of the plasma peak. 
All patients of both groups responded to the treatment showing either a complete or a partial 
tumor remission.  
Due to the small patient number and the fact that we just now determined the tumor and plasma 
peaks for Fospeg in the feline species, a true comparison between the effectiveness of the 2 
formulations is not yet possible. Fospeg appears to be at least as effective as Foscan®.   
 
In conclusion, we have shown that the new, liposomal formulation of m-THPC is a safe drug, 
causing no noticeable acute side effects in any cat in the present study. With Fospeg, important 
progress for PDT could be achieved. The combination of a higher selectivity and significantly 
earlier tumor and plasma peaks will result in a more efficient and eventually more effective 
PDT protocol. 
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Figure 1 Tumor and skin fluorescence intensities as a function of time after injection of either 
Foscan or Fospeg  (median values of all patients; error bars indicate the standard 
deviation, SD); in the right upper corner the lower three plots are shown as a 
magnified view with an enlarged scale for the fluorescence intensities  
 
 
Figure 2 Bioavailability of either Foscan (=1) or Fospeg (=2) in the tumor during the first 16 h 
after injection (Area under the curve after 16 hours; AUC16): Box plot investigation 
 
 
Figure 3 Plasma m-THPC concentration as a function of time after injection of either Foscan 
or Fospeg  (median values of all patients; error bars indicate the standard deviation, 
SD) 
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Figure 3  
Table 1     Tissue fluorescence parameters for Foscan (Patient 1-3) and Fospeg (Patient 4-10) 
 
 
Patient 
 
Maximal 
fluorescence 
intensities (tumor) 
 
 
Time of maximal 
fluorescence 
intensities (tumor) 
(h) 
 
Maximal 
tumor to tissue 
ratio 
 
Time of maximal 
tumor to tissue ratio 
(h) 
 
AUC16∗  
tumor 
 
AUC16∗  
skin 
 
AUC16∗  
tumor/ 
skin 
 
1 
 
78.72 
 
36 
 
1.79 
 
4 
 
334.41 
 
232.59 
 
1.44 
 
2 
 
249.03 
 
36 
 
4.81 
 
6 
 
1081.73 
 
359.29 
 
3.01 
 
3 
 
154.89 
 
48 
 
 2.45  
 
24 
 
900.73 
 
582.00 
 
1.55 
 
Mean 
 
160.88 
 
40.00 
 
3.02 
 
11.33 
 
772.29 
 
391.29 
 
2.00 
 
Median 
 
154.89 
 
36.00 
 
2.45 
 
6.00 
 
900.73 
 
359.29 
 
1.55 
 
SD 
 
85.31 
 
6.93 
 
1.59 
 
11.02 
 
389.87 
 
176.89 
 
0.88 
 
4 
 
279.00 
 
6 
 
18.34  
 
6 
 
3559.33 
 
391.33 
 
9 
 
5 
 
407.33 
 
10 
 
11.98  
 
10 
 
4332.50 
 
420.50 
 
10.30 
 
6 
 
234.67 
 
10 
 
 7.82  
 
10 
 
1989.00 
 
478.33 
 
4.16 
 
7 
 
212.00 
 
7 
   
 3.95  
 
7 
 
2244.17 
 
1188.50 
 
1.89 
 
8 
 
99.33 
 
7 
  
  3.47  
 
7 
 
4332.50 
 
420.50 
 
10.30 
 
9 
 
350.67 
 
5 
 
 13.66  
 
5 
 
2428.50 
 
376.50 
 
6.45 
 
10 
 
346.67 
 
6 
 
16.00 
 
6 
 
2781.50 
 
427.72 
 
6.50 
 
Mean 
 
275.67 
 
7.29 
 
10.75 
 
7.29 
 
3095.38 
 
529.05 
 
6.94 
 
Median 
 
279.00 
 
7.00 
 
11.98 
 
7.00 
 
2781.50 
 
420.50 
 
6.50 
 
SD 
 
103.96 
 
1.98 
 
 5.82 
 
1.98 
 
980.48 
 
292.55 
 
3.18 
 
∗ Area under the curve 16 hours after injection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2     Plasma parameters for Foscan (Patient 1-3) and Fospeg (Patient 4-10) 
 
 
Patient 
 
C max
§  
(ng/ml 
plasma) 
 
 
T max
¶
 
(h) 
 
t ½ distribution
#
 (h) 
(hour 0-16) 
 
t ½ elimination
##
 (h) 
(hour 16-72) 
 
Elimination 
Rate Constant 
(hour 0-16) 
 
Elimination 
Rate Constant 
(hour 16-72) 
 
AUC16∗ 
(ng x h x ml-1) 
 
AUC72∗∗ 
(ng x h x ml-1) 
 
1 
 
458.81 
 
8 
 
56.86 
 
20.32 
 
0.01 
 
 
 
0.03 
 
4974.64 
 
7765.53 
 
2 
 
238.12 
 
6 
 
44.62 
 
23.25 0.02 
 
 
0.03 
 
3390.01 
 
7039.13 
 
3 
 
597.22 
 
6 
 
38.75 
 
18.35 
 
0.02 
 
0.04 
 
8217.56 
 
19193.93 
 
Mean 
 
431.38 
 
6.67 
 
46.74 
 
20.64 
 
0.02 
 
0.03 
 
5527.40 
 
11332.86 
 
Median 
 
458.81 
 
6.00 
 
44.62 
 
20.32 
 
0.02 
 
0.03 
 
4974.64 
 
7765.53 
 
SD 
 
181.12 
 
1.15 
 
9.24 
 
2.47 
 
0.00 
 
0.00 
 
2460.79 
 
6817.56 
 
4 
 
1690.10 
 
0 
 
6.97 
 
22.35 
 
0.10 
 
0.03 
 
13341.84 
 
22050.53 
 
5 
 
854.92 
 
0 
 
6.45 
 
17.71 
 
0.11 
 
0.04 
 
5975.30 
 
9418.44 
 
6 
 
693.74 
 
0 
 
9.61 
 
14.36 
 
0.07 
 
0.05 
 
6591.53 
 
11190.45 
 
7 
 
1757.00 
 
0 
 
6.37 
 
19.83 
 
0.11 
 
0.03 
 
11294.70 
 
17921.64 
 
8 
 
1523.30 
 
0 
 
14.42 
 
44.66 
 
0.05 
 
0.02 
 
17593.76 
 
39756.32 
 
9 
 
1789.45 
 
0 
 
7.95 
 
13.55 
 
0.09 
 
0.05 
 
13736.35 
 
26490.77 
 
10 
 
911.04 
 
0 
 
13.72 
 
27.82 
 
0.05 
 
0.02 
 
10671.77 
 
22260.78 
 
Mean 
 
1317.08 
 
0 
 
9.36 
 
22.90 
 
0.08 
 
0.03 
 
11315.03 
 
21298.42 
 
Median 
 
1523.30 
 
0 
 
7.95 
 
19.83 
 
0.09 
 
0.03 
 
11294.70 
 
22050.53 
 
SD 
 
477.03 
 
0 
 
3.41 
 
10.76 
 
0.03 
 
0.01 
 
4095.35 
 
10196.85 
 
§ Maximal plasma concentration 
¶ Time point of maximal plasma concentration 
# Distribution half-life 
## Elimination half-life 
∗ Area under the curve 16 hours after injection 
∗∗ Area under the curve 72 hours after injection 
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